Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov;100(5):423-426.
doi: 10.1002/cpt.405. Epub 2016 Jul 21.

Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration

Affiliations
Free PMC article

Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration

S W Yee et al. Clin Pharmacol Ther. .
Free PMC article

Abstract

Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.

Figures

Figure 1
Figure 1. An infographic of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration
The website describing the collaboration can be found at http://www.pgrn.org/pgrn-riken.html
Figure 2
Figure 2. Eight study areas of PGRN-RIKEN Collaborative studies
A total of 41 studies were initiated through this international collaboration. Among the studies, 37 were genomewide genotyping and 4 were sequencing studies of top locus/candidate genes.

Similar articles

See all similar articles

Cited by 2 articles

MeSH terms

Feedback